Skip to content

Teva Phamaceutical's CEO steps down, temporarily replaced by board chairman

Teva Pharmaceutical Industries announced Monday that its president and CEO Erez Vigodman was stepping down, effective immediately, and that Yitzhak Peterburg, chairman of Teva's board of directors, will be the interim chief executive officer.

Teva has begun a search for a permanent CEO, said the Israel-based company with North American headquarters in North Wales, Montgomery County.

The announcement came after the stock market closed Monday, and just a week after a federal court in Delaware rejected four of Teva's claims of patent infringement on its top-selling multiple sclerosis medicine Copaxone.

Teva's shares closed down 0.26 percent, or nine cents, to $34.35. The stock has traded between $32.11 and $59.35 in the last 52 weeks.

"The company is focusing on executing opportunities to enhance value for shareholders," Yitzhak said in a statement.

Vigodman said, "I believe that now is the right time for me to step down." Teva, which is scheduled to report fourth-quarter 2016 earnings next Monday, employs 2,000 in the Philadelphia area.